港股收評:午後轉升!科指升0.48%止步3連跌,生物醫藥股強勢,汽車股繼續走低
港股午後拉昇,三大指數均由跌轉升。恒生科技指數升0.48%止步3連跌行情,恒生指數、國企指數分別上升0.43%及0.38%,交易量延續低迷。盤面上,作為市場風向標的大型科技股普遍回暖,美團績後收升2%,盤初曾跌超5%,網易升1.5%,阿里巴巴升約1%,小米、騰訊飄紅,京東仍下跌1%;創新藥再迎重要催化!頂級腫瘤學年會召開在即,生物醫藥股全天表現強勢,其中,先聲藥業升近9%,綠葉製藥、康龍化成、聯邦制藥升超6%,信達生物、石藥集團、康臣藥業升超5%;在線教育股、航空股、啤酒股、芯片股、體育用品股齊升。另一方面,黃金股多數表現低迷,赤峯黃金、招金礦業跌超4%;電動車內卷加劇,行業情緒緊繃,汽車股再度下跌,蔚來汽車、吉利汽車、比亞迪股份等走弱,汽車經銷商股、汽車零件股跟跌。此外,派格生物醫藥-B首日上市大跌近26%。(格隆匯)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.